We noticed you are on our US page. Want to switch regions? Choose from the options:

Clinical trials

We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients

Image Alt Text

Ongoing clinical trials

Curium ECLIPSE

diseaseName

This is a prospective, randomized, open-label, multicenter Phase 3 study evaluating the efficacy and safety of 177Lu-PSMA-I&T versus a switch in standard of care hormone therapy in men with metastatic

Sanofi IONA-MM OBS16577

Cancer

A prospective, non-interventional, multinational, observational study with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM)

EA5163

Cancer

EA5163-A Randomized, Phase III Study of Firstline Immunotherapy with or without Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC)

AstraZeneca D4194C00008

Cancer

A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Mirati 007

diseaseName

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Prostate cancer

EA8183

Prostate cancer

A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis

Head and neck cancer

Veru ARTEST V3002401

This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion.

Helsinn ANAM-17-20

Cancer

A phase 3, randomized, double-blind, placebocontrolled, multicenter study

Pfizer C4221016

diseaseName

A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab

Veru V2011801

diseaseName

To assess the safety and tolerability of sabizabulin monotherapy, and Trodelvy/sabizabulin combination therapy

Novocure LUNAR EF-24

Cancer

To test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while/on/after platinum based treatment

Breast cancer

BR007

Breast cancer

A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER

Veru ARTEST V3002401

This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion.

SpaceOar SABRE

diseaseName

To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate cancer.

Momenta MOM-M281-006

diseaseName

The primary objective is to evaluate the efficacy of M281 in patients with warm autoimmune hemolytic anemia (wAIHA).

Nektar Propel 20-214-36

diseaseName

This is a multicenter, randomized, open-label, Phase 2/3 study

Seattle Genetics SGNLVA-005

Cancer

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Natera 20-041-NCP

diseaseName

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Mirati 012

diseaseName

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Pancreatic cancer

A021602

Pancreas

RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)

Checkmate CMP-001-010

diseaseName

A multicenter, open-label, phase 2 study of intratumoral CMP-001 in combination withintravenous nivolumab in subjects with refractory unresectable or metastatic melanoma

Lilly JPCW

diseaseName

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study

Checkmate CMP-001-009

diseaseName

A multicenter, open-label, Phase 2 study of intratumoral CMP-001 in combination withntravenous PD-1–blocking antibody in subjects with selected types of advanced or metastatic cancer

S1929

Cancer

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib

BioAtla 3021

diseaseName

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

LIlly JZJX

diseaseName

LIBRETTO-432:A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in patients with Stage IB-IIIA RET fusion-Positive NSCLC

Prostate cancer

GU011

Prostate cancer

A PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC RADIOTHERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE CANCER (NRG PROMETHEAN)

Prostate cancer

GU010

Prostate cancer

PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)

Breast cancer

EA1183

Breast cancer

FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE

Breast cancer

BR004

Breast cancer

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Prostate cancer

GU002

Prostate cancer

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel

GU009

Cancer

Parallel phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurre

Lung cancer

CC003

Lung cancer

A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

S1802

Prostate cancer

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Lung cancer

EA5181

Lung cancer

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable

BGB-3111-215

diseaseName

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrut

UTX-TGR-205-2b

diseaseName

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk

Bladder cancer

S1806

Bladder cancer

SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive

Lung cancer

S1914

Lung cancer

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

DCISionRT

diseaseName

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

Prostate cancer

RTOG 3506

Prostate cancer

STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with PostProstatectomy PSA Recurrences with Aggressive

BMS CA209-651

diseaseName

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of t

BMS CA209-234

Cancer

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

MROQC

Cancer

MROQC

TG Therapeutics 304

diseaseName

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic

UTX-TGR-205

diseaseName

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)